Vol 7, No 2 (2022)
Original article
Published online: 2022-06-17

open access

Page views 4257
Article views/downloads 352
Get Citation

Connect on Social Media

Connect on Social Media

Assessment of the chemerin, IL-6, and IL-23 correlations and their impact on CRC progression: An observational study

Julia Robotycka1, Sylwia Mielcarska1, Miriam Dawidowicz2, Agnieszka Kula2, Błażej Ochman1, Bogusława Strzałkowska1, Tomasz Niebudek1, Dariusz Waniczek2, Elżbieta Świętochowska1
Medical Research Journal 2022;7(2):157-163.

Abstract

Introduction: The role of proinflammatory cytokines is said to be crucial in the development of colorectal cancer (CRC). IL-6, IL-23, and chemerin have all been proven to take part in tumor growth and progression. Aim of the study: to determine the level of chemerin and the concentrations of interleukin-6 (IL-6) and interleukin- 23 (IL-23) in the tumor and margin specimens of CRC in relation to histological grade and TNM staging. Material and methods: The study involved 49 samples of tumor and margin tissues obtained from CRC patients. To assess the concentration of chemerin, IL-6, and IL-23, commercially available enzyme-linked immunosorbent assay (ELISA) kits were used. Results: There was no difference in chemerin concentration between the tumor and margin. We found significantly increased levels of IL-6 in tumor tissue compared to margin tissue and higher concentrations of IL-23 in margin tissue than in tumor tissue. Tumor levels of chemerin were significantly correlated with those of IL-23, while its margin concentrations were associated with margin concentrations of IL-6. Additionally, tumor levels of IL-23 were positively correlated with margin levels of IL-6. Conclusions: Chemerin might play an important role in CRC progression through its association with cytokine expression. More studies are needed to investigate the possible role of IL-6, IL-23, and chemerin as potential markers in the development of CRC.

Article available in PDF format

View PDF Download PDF file

References

  1. Zeng J, Tang ZH, Liu S, et al. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017; 23(10): 1780–1786.
  2. World Cancer Research Fund. Worldwide cancer data. https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ (9.05.2022).
  3. Centers for Disease Control and Prevention. An Update on Cancer Deaths in the United States.: Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control; 2022.
  4. Akimoto N, Ugai T, Zhong R, et al. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021; 18(4): 230–243.
  5. Jasperson K, Tuohy T, Neklason D, et al. Hereditary and Familial Colon Cancer. Gastroenterology. 2010; 138(6): 2044–2058.
  6. Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients. 2019; 11(1).
  7. Roguska J, Zubkiewicz-Kucharska A. Chemerin as an early marker of metabolic syndrome. Pediatric Endocrinology Diabetes and Metabolism. 2018; 24(1): 45–51.
  8. Helfer G, Wu QF. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018; 238(2): R79–R94.
  9. Eichelmann F, Schulze MB, Wittenbecher C, et al. Association of chemerin plasma concentration with risk of colorectal cancer. JAMA Netw Open. 2019; 2(3): e190896.
  10. Komoda H, Tanaka Y, Honda M, et al. Interleukin-6 levels in colorectal cancer tissues. World J Surg. 1998; 22(8): 895–898.
  11. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014; 2(4): 288–294.
  12. Waldner MJ, Foersch S, Neurath MF. Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci. 2012; 8(9): 1248–1253.
  13. Lan F, Zhang Le, Wu J, et al. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis. 2011; 26(12): 1511–1518.
  14. Adamo V, Franchina T, Minciullo PL, et al. Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. J Cell Physiol. 2011; 226(11): 3032–3034.
  15. Yan J, Smyth MJ, Teng MWL. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. 2018; 10(7).
  16. Alkady MM, Abdel-Messeih PL, Nosseir NM. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem. 2018; 37(3): 313–319.
  17. Chonov DC, Ignatova MM, Ananiev JR, et al. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci. 2019; 7(14): 2391–2398.
  18. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999; 85(12): 2526–2531, doi: 10.1002/(sici)1097-0142(19990615)85:12<2526::aid-cncr6>3.0.co;2-3.
  19. Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003; 171(2): 600–607.
  20. Suzuki H, Ogawa H, Miura K, et al. IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol Lett. 2012; 4(2): 199–204.
  21. Ljujic B, Radosavljevic G, Jovanovic I, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010; 41(3): 182–189.
  22. FM R, S H, MA Z, et al. Evaluation of expression pattern of vascular endothelial growth factor (VEGF) and interleukin-23 (IL-23) genes in human colorectal tumors. Journal of Molecular and Genetic Medicine. 2018; 12(1).
  23. Wang J, Xu K, Wu J, et al. The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. BMC Cancer. 2012; 12: 418.
  24. Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009; 9: 155.
  25. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006; 26(5B): 3905–3911.
  26. Shiga K, Hara M, Nagasaki T, et al. Preoperative serum interleukin-6 is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016; 2016: 9701574.
  27. Stanilov N, Miteva L, Deliysky T, et al. Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Laboratory Medicine. 2010; 41(3): 159–163.
  28. Zhang Le, Li J, Li Li, et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. 2014; 35(6): 1330–1340.
  29. Wang K, Karin M. The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol. 2015; 33(Suppl 92): S87–90.
  30. Elessawi DF, Alkady MM, Ibrahim IM. Diagnostic and prognostic value of serum IL-23 in colorectal cancer. Arab J Gastroenterol. 2019; 20(2): 65–68.